EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model.

ABSTRACT:

Background

Pulmonary arterial hypertension (PAH) is a progressive pulmonary arteriopathy characterized by vascular remodeling and subsequent increases in pulmonary vascular resistance, which further develops into right ventricular failure and death. Currently, PAH management targets pulmonary vasoconstriction, though there is an unmet medical need to develop therapeutics focusing on pulmonary vascular remodeling. Recently, we reported that 5,6-diHETE lactone (EPA-L, a stable metabolite of the EPA fatty acid) elicits vasodilation and blood-pressure-lowering effect in 5/6 nephrectomy hypertensive rats and vasodilation in human arterioles by an endothelial-dependent mechanism.

Aim

We aimed to investigate the effect of EPA-L in a monocrotaline (MCT)-induced rat model of PAH.

SUBMITTER: Dhananjayan K 

PROVIDER: S-EPMC12287610 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature